focus -WSS

focus

author：comprehensive 2025-09-04 21:59:04 - browse：563

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： GSK’s asthma push continues as drug succeeds in Phase 3 trials

Wikipedia

WSS

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Empower primary care with adequate payments and technology

Brain technologies pose threats that are all too real, experts warn

AI for drug discovery: Experts on separating hype from reality

Class action alleges UnitedHealth concealed DOJ probe

Class action alleges UnitedHealth concealed DOJ probe

knowledge

focus

hotspot

Sports medicine is finally prioritizing gender equality

Chemotherapy before breast cancer surgery might fuel metastasis

Medical leaders decry Supreme Court decision on affirmative action

HHS's proposed rule does nothing to address the climate crisis

FDA approval of Sarepta Duchenne genetic therapy gives me hope

HHS's proposed rule does nothing to address the climate crisis

Novavax promises a turnaround & Lilly roils the obesity market

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Activists slam private health insurers over coverage restrictions

Empower primary care with adequate payments and technology

hotspot

How a small hospital in rural Puerto Rico survived Hurricane Maria

Primary care doctor shortage won't be solved by free med school tuition

AltruBio raises $225 million to develop ulcerative colitis drug

Brain technologies pose threats that are all too real, experts warn

Brain technologies pose threats that are all too real, experts warn

Brain MRIs reveal impact of 'toxic stress' on Black children

knowledge

Wikipedia

Wikipedia

explore